Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Guided Posters

Acromegaly and GH

ea0063gp48 | Acromegaly and GH | ECE2019

Prolonged diagnostic delay in acromegaly is associated with long-term morbidity and excess mortality: data from a nationwide study

Esposito Daniela , Ragnarsson Oskar , Johannsson Gudmundur , Olsson Daniel S

Background: Clinical features of acromegaly develop insidiously and the diagnosis is often delayed. However, diagnostic delay (DD) in acromegaly has not been systematically investigated. Our primary aim was to investigate DD in a nationwide cohort of patients with acromegaly. Secondary aim was to study the impact of DD on morbidity and mortality.Methods: Adult patients diagnosed with acromegaly between 2001 and 2013 were identified in the Swedish Nationa...

ea0063gp49 | Acromegaly and GH | ECE2019

Pharmacokinetics of somapacitan in individuals with renal impairment: an open-label, parallel group, phase 1 study

Bentz Damholt Birgitte , Bisgaard Charlotte , Louise Dombernowsky Sarah , Hojby Rasmussen Michael

Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative developed for once-weekly administration that acts directly or indirectly via insulin-like growth factor I (IGF-I). As renal impairment may affect drug metabolism and excretion, we report data from an open-label, parallel group, phase I trial (NCT03186495) investigating the pharmacokinetic and pharmacodynamic properties, and safety of somapacitan in individuals with varying degrees of impair...

ea0063gp50 | Acromegaly and GH | ECE2019

Sleep disorders and cognitive dysfunction in acromegaly

Dassie Francesca , Wennberg Alexandra , Lorusso Riccardina , Parolin Matteo , Russo Lucia , Mazzocut Sara , Benavides-Varela Silvia , De Carlo Eugenio , Martini Chiara , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: In the general population, sleep disorders are associated with an increased risk of cognitive impairment; moreover, people with dementia often have sleep disturbances. The prevalence of sleep disorders, such as sleep apnea, in acromegalic patients is higher than in the general population, and they may have a higher risk of cognitive impairment due to acromegaly treatment (i.e. Radiotherapy) or cardiovascular comorbidities. In the literature, data about the relation...

ea0063gp51 | Acromegaly and GH | ECE2019

Prognostic value of short-acting pasireotide test for response prediction to pasireotide LAR in patients with acromegaly resistant to first-generation analogs. Can a short-acting pasireotide test predict the response of long-acting pasireotide treatment in patients with acromegaly resistant to first generation somatostatin analogs?

Majos Agnieszka , Stelmachowska-Banaś Maria , Czajka-Oraniec Izabella , Gęsior Jakub , Zgliczyński Wojciech

Introduction: The treatment of choice in acromegaly is a transsphenoidal surgery of a growth hormone (GH) - producing pituitary adenoma. In patients with persistent acromegaly after surgery medical treatment is recommended. First generation somatostatin analogs: lanreotide autogel and octreotide LAR are effective in 25% to 45% of patients depending on population and study protocol. Second-generation somatostatin analog – pasireotide LAR seems to be more effective. The pos...

ea0063gp52 | Acromegaly and GH | ECE2019

Final height in childhood onset hypopituitarism

Esposito Andrea , Improda Nicola , Moracas Cristina , Barbieri Flavia , Alfano Sara , Capalbo Donatella , Salerno Mariacarolina

Background: Growth hormone (GH) deficiency(GHD) in childhood is associated with impairment in linear growth. GH therapy enables the achievement of normal adult height in most cases. The response is variable and factors influencing height outcome are still not clearly defined.Objective: To evaluate near adult height (NAH) in a single center cohort of childhood onset GHD patients treated with GH and investigate main predictors of final height (FH).<p c...

ea0063gp53 | Acromegaly and GH | ECE2019

Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency (AGHD) confirmed in a 53-week REAL-1 trial extension

Johannsson Gudmundur , Gordon Murray , Rasmussen Michael Hojby , Hakonsson Ida Holme , Svaerke Claus , Tahara Shigeyuki , Takano Koji , Biller Beverly MK

Background: Following the 34-week, double-blind, placebo-controlled main phase of REAL-1 (NCT02229851), this open-label trial extension evaluated efficacy and safety of somapacitan in patients aged 23–79 years with AGHD, for an additional 52 weeks (8 weeks’ dose titration followed by 44 weeks’ fixed dose treatment; 86 weeks’ treatment in total).Methods: Patients completing the main trial entered the extension: 1) somapacitan-treated p...

ea0063gp54 | Acromegaly and GH | ECE2019

Pharmacokinetics in patients with prolactinomas

Fedorova Natalia , Dzeranova Larisa , Pigarova Ekaterina , Vorotnikova Svetlana

Introduction: Prolactinoma is the most commonly occurring hormonally active pituitary tumor. In most cases, dopamine receptor agonists (DA) as a monotherapy are effective. However, approximately 10% of patients with prolactinomas fail to achieve normalization of serum prolactin levels during treatment with DA, which indicates resistance to this group of drugs.Aims: The goal was to study the pharmacokinetics of cabergoline in patients harboring prolactino...

ea0063gp55 | Acromegaly and GH | ECE2019

Acromegaly do not increase the risk of vertebral fractures: a retrospective and prospective study on 50 patients

Hochman Clarisse , Plard Charlotte , Le Bras Maelle , Le Goff Benoit , Maugars Yves , Guillot Pascale , Cariou Bertrand , Drui Delphine

Context: Previous studies suggest that patients with acromegaly were at higher risk of vertebral fractures (VFs) despite normal bone mineral density (BMD). However, these patients could have several associated endocrine deficits known to increase the fracture risk, such as hypogonadism. In addition, patients with acromegaly have radiological deformations of the spine, called Erdheim’s syndrome, which can overestimate the radiological VFs.Objective: ...

ea0063gp56 | Acromegaly and GH | ECE2019

Sclerostin and fracture risk assessment in acromegaly

Halupczok-Żyła Jowita , Jawiarczyk-Przybyłowska Aleksandra , Zembska Agnieszka , Bolanowski Marek

Introduction: Sclerostin is well-known as an inhibitor of bone formation but also promotes bone resorption. Acromegaly is a disease characterized by increased bone turnover and higher vertebral fracture risk.Purpose: The aim of the study was to determine sclerostin levels in acromegaly patients with regard to the disease activity. We also evaluated the associations between sclerostin and random growth hormone (GH), insulin-like growth factor 1 (IGF-I), l...

ea0063gp57 | Acromegaly and GH | ECE2019

Biochemical control was sustained with long-acting pasireotide in patients with uncontrolled acromegaly over continued treatment with first-generation somatostatin analogues (SSAs): Results from the extension of phase 3b, open-label study

Gadelha Monica , Colao Annamaria , Bex Marie , Mukherjee Rishav , Bourad Catherine , Maamari Ricardo , Raverot Gerald

Background: In a phase 3b, open-label study (NCT02354508) assessing efficacy and safety of long-acting pasireotide in patients with uncontrolled acromegaly after ≥3 months of treatment with first-generation SSAs, 18/123 (15%) patients achieved the primary endpoint of mean growth hormone (mGH) <1.0 μg/l and insulin-like growth factor-1 (IGF-1) <ULN (upper limit of normal) at week 36. Here, we present the results from the extension phase of this study.<p c...

ea0063gp58 | Acromegaly and GH | ECE2019

ACROSTUDY – safety and efficacy in a cohort of 110 Naïve patients with acromegaly treated with pegvisomant

Wajnrajch Michael , Gomez Roy , Hey-Hadavi Judith , Kelepouris Nikoletta , van der Lans Joli , Loftus Jane , Camacho-Hubner Cecilia , Fleseriu Maria , Salvatori Roberto , Cara Jose , Palladino Andrew

Background: ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV). This commitment was fulfilled in Jan 2013. ACROSTUDY was later amended to enroll an additional 110 patients that were naïve/semi-naive to PEGV treatment. Semi-naïve patients are defined as not having received PEGV therapy for at least 6 months p...

ea0063gp59 | Acromegaly and GH | ECE2019

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Bima Chiara , Frara Stefano , Mirra Federica , Donfrancesco Federico , Fleseriu Cara Maria , Fleseriu Maria , Giustina Andrea , Laura De Marinis , Pontecorvi Alfredo

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

ea0063gp60 | Acromegaly and GH | ECE2019

Metabolic outcome in adolescents with growth hormone deficiency during transition phase

Improda Nicola , Anselmi Federica , Alfano Sara , D'Acunzo Ida , Bufalo Lorenzo , Capalbo Donatella , Salerno Mariacarolina

Background: There is concern that adolescents with childhood-onset GHD (COGHD) and persistent GH deficiency may be exposed to multiple metabolic risks after GH treatment withdrawal at the attainment of final height (FH).Aim: Aim of our study is to retrospectively compare growth response and metabolic profile in isolated idiopathic COGHD adolescents with permanent GH deficiency in comparison to GHD subjects who normalized their GH response at transition p...